Advertisement

Bilberry

  • Timothy S. Tracy
Part of the Forensic Science and Medicine book series (FSM)

Abstract

Although bilberry has been used for a variety of conditions, it has only been shown to be moderately effective in the treatment of retinopathy. No other clinical studies have demonstrated bilberry’s effectiveness for any other conditions. Fortunately, adverse effects from ingesting bilberry are minimal.

Key Words

Vaccimium myritillus glycosamino glycans cancer prevention vascular permeability visual acuity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cignarella A, Nastasi M, Cavalli E, Puglisi L. Novel lipid-lowering properties of Vaccinium myrtillus L. leaves, a traditional antidiabetic treatment, in several models of rat dyslipidaemia: a comparison with ciprofibrate. Thromb Res 1996;84:311–322.PubMedCrossRefGoogle Scholar
  2. 2.
    Muth ER, Laurent JM, Jasper P. The effect of bilberry nutritional supplementation on night visual acuity and contrast sensitivity. Altern Med Rev 2000;5:164–173.PubMedGoogle Scholar
  3. 3.
    Monograph. Vaccinium myrtillus (bilberry). Altern Med Rev 2001;6:500–504.Google Scholar
  4. 4.
    Magistretti MJ, Conti M, Cristoni A. Antiulcer activity of an anthocyanidin from Vaccinium myrtillus. Arzneimittelforschung 1988;38:686–690.PubMedGoogle Scholar
  5. 5.
    Cristoni A, Magistretti MJ. Antiulcer and healing activity of Vaccinium myrtillus anthocyanosides. Farmaco [Prat] 1987;42:29–33.Google Scholar
  6. 6.
    Bonati A. How and why should we standardize phytopharmaceutical drugs for clinical validation? J Ethnopharmacol 1991;32:195–197.PubMedCrossRefGoogle Scholar
  7. 7.
    Detre Z, Jellinek H, Miskulin M, Robert AM. Studies on vascular permeability in hypertension: action of anthocyanosides. Clin Physiol Biochem 1986;4:143–149.PubMedGoogle Scholar
  8. 8.
    Roy S, Khanna S, Alessio HM, et al. Anti-angiogenic property of edible berries. Free Radic Res 2002;36:1023–1031.PubMedCrossRefGoogle Scholar
  9. 9.
    Laplaud PM, Lelubre A, Chapman MJ. Antioxidant action of Vaccinium myrtillus extract on human low density lipoproteins in vitro: initial observations. Fundam Clin Pharmacol 1997; 11:35–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Scharrer A, Ober M. [Anthocyanosides in the treatment of retinopathies (author’s translation)]. Klin Monatsbl Augenheilkd 1981; 178:386–389.PubMedCrossRefGoogle Scholar
  11. 11.
    Perossini M, Guidi G, Chiellini S, Siravo D. Diabetic and hypertensive retinopathy therapy with Vaccinium myrtillus anthocyanosides (Tegens) double blind placebocontrolled clinical trial. Ann Ottalmol Clin Ocul 1987; 113:1173–1190.Google Scholar
  12. 12.
    Zadok D, Levy Y, Glovinsky Y. The effect of anthocyanosides in a multiple oral dose on night vision. Eye 1999;13(Pt 6):734–736.PubMedGoogle Scholar
  13. 13.
    Belleoud L, Leluan D, Boyer Y. Study on the effects of anthocyanin glycosides on the nocturnal vision of air traffic controllers. Rev Med Aeronaut Spatiale 1966; 18:3–7.Google Scholar
  14. 14.
    Jayle GE, Aubert L. Action des glucosides d’anthocyanes sur la vision scotopique et mesopique du subjet normal. Therapie 1964;19:171–185.PubMedGoogle Scholar
  15. 15.
    Terrasse J, Moinade S. Premiers reultats obtenus avec un nouveau facteur vitaminique P „les anthocanosides“ extraits du Vaccinium myrtillus. Press Med 1964;72:397–400.Google Scholar
  16. 16.
    Gloria E, Peria A. Effect of anthocyanosides on the absolute visual threshold. Ann Ottalmol Clin Ocul 1966;92:595–607.PubMedGoogle Scholar
  17. 17.
    Junemann G. [On the effect of anthocyanosides on hemeralopia following quinine poisoning]. Klin Monatsbl Augenheilkd 1967;151:891–896.PubMedGoogle Scholar
  18. 18.
    Caselli L. Clinical and electroretinographic study on activity of anthocyanosides. Arch Med Intern 1985;37:29–35.Google Scholar
  19. 19.
    Head KA. Natural therapies for ocular disorders, part two: cataracts and glaucoma. Altern Med Rev 2001;6:141–166.PubMedGoogle Scholar
  20. 20.
    Bravetti G. Preventive medical treatment of senile cataract with vitamin E and anthocyanosides: clinical evaluation. Ann Opthalmol Clin Ocul 1989; 115:109–116.Google Scholar
  21. 21.
    Saija A, Princi P, D’Amico N, De Pasquale R, Costa G. Effect of Vaccinium myrtillus anthocyanins on triiodothyronine transport into brain in the rat. Pharmacol Rev 1990;22:59–60.Google Scholar
  22. 22.
    Mazza G, Kay CD, Cottrell T, Holub BJ. Absorption of anthocyanins from blueberries and serum antioxidant status in human subjects. J Agric Food Chem 2002;50:7731–7737.PubMedCrossRefGoogle Scholar
  23. 23.
    Cao G, Muccitelli HU, Sanchez-Moreno C, Prior RL Anthocyanins are absorbed in glycated forms in elderly women: a pharmacokinetic study. Am J Clin Nutr 2001;73:920–926.PubMedGoogle Scholar
  24. 24.
    Bitsch I, Janssen M, Netzel M, Strass G, Frank T. Bioavailability of anthocyanidin-3-glycosides following consumption of elderberry extract and blackcurrant juice. Int J Clin Pharmacol Ther 2004;42:293–300.PubMedGoogle Scholar
  25. 25.
    Morazzoni P, Bombardelli E, Vaccinium myrtillus L. Fitoterapia 1996;68:3–29.Google Scholar
  26. 26.
    FDA. Bilberry. In: Center for Food Safety and Applied Nutrition OoPAEAfad, 2004. Available at http://www.cfsan.fda.gov/~comm/ds-econ4.html. Last accessed: Sept. 2006.
  27. 27.
    Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines (translated by S. Klein). Austin American Botanical Council Boston, 1998.Google Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Timothy S. Tracy

There are no affiliations available

Personalised recommendations